Skip to main content
. 2016 Jul 29;34(35):4213–4220. doi: 10.1016/j.vaccine.2016.06.050

Table 1.

Gavi co-financing policies 2008–2017.

2008–2011 2012–2016 2017–
Country groups
  • 1.

    Fragile

  • 2.

    Poorest

  • 3.

    Intermediate

  • 4.

    Least poor
  • 1.

    Low-income

  • 2.

    Intermediate

  • 3.

    Graduating
  • 1.

    Initial self-financing

  • 2.

    Preparatory transition

  • 3.

    Accelerated transition
Initial co-financing levels per vaccine dose
  • ▪

    US$ 0.10 – US$ 0.30

  • ▪

    Amounts differed for first and subsequent approved vaccines

 US$ 0.20 US$ 0.20
Annual increase in co-financing per dose 15% for the least poor group 15% for the intermediate group 15% for the preparatory transition group
Trajectory for transitioning out of support None specified Graduating group:
  • ▪

    Linear increase to reach full vaccine price after 5 years

 Accelerated transition group:
  • ▪

    Linear increase to reach full vaccine price after 5 years
Co-financing linked to vaccine price No link Graduating group:
  • ▪

    Paying linearly towards full vaccine price

 Preparatory transition group:
  • ▪

    Co-financing for individual vaccine differ according to vaccine prices


Accelerated transition group:
  • ▪

    Paying linearly towards full vaccine price